Extra-Skeletal Effects of Vitamin D
Abstract
:1. Introduction
2. Immune and Anti-Inflammatory Effects
2.1. Type 1 Diabetes
2.2. Multiple Sclerosis
2.3. Rheumatoid Arthritis
2.4. Systemic Lupus Erythematosus (SLE) and Juvenile Dermatomyositis
2.5. Psoriasis
2.6. Inflammatory Bowel Disease (IBD)
2.7. Food Allergies
2.8. Chronic Hepatitis B and C
2.9. Asthma and Respiratory Infections
3. Metabolic Syndrome and Type 2 Diabetes Mellitus
4. Cancer
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Misra, M.; Pacaud, D.; Petryk, A.; Collett-Solberg, P.F.; Kappy, M. Vitamin D deficiency in children and its management: Review of current knowledge and recommendations. Pediatrics 2008, 122, 398–417. [Google Scholar] [CrossRef] [PubMed]
- Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J. Clin. Endocrinol. Metab. 2012, 97, 1153–1158. [Google Scholar] [CrossRef] [PubMed]
- Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911–1930. [Google Scholar] [CrossRef] [PubMed]
- Ross, A.C.; Manson, J.E.; Abrams, S.A.; Aloia, J.F.; Brannon, P.M.; Clinton, S.K.; Durazo-Arvizu, R.A.; Gallagher, J.C.; Gallo, R.L.; Jones, G.; et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J. Clin. Endocrinol. Metab. 2011, 96, 53–58. [Google Scholar] [CrossRef] [PubMed]
- Guo, J.; Lovegrove, J.A.; Givens, D.I. 25(OH)D3-enriched or fortified foods are more efficient at tackling inadequate vitamin D status than vitamin D3. Proc. Nutr. Soc. 2018, 77, 282–291. [Google Scholar] [CrossRef] [PubMed]
- Tsoukas, C.D.; Provvedini, D.M.; Manolagas, S.C. 1,25-dihydroxyvitamin D3: A novel immunoregulatory hormone. Science 1984, 224, 1438–1440. [Google Scholar] [CrossRef] [PubMed]
- Bhalla, A.K.; Amento, E.P.; Clemens, T.L.; Holick, M.F.; Krane, S.M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab. 1983, 57, 1308–1310. [Google Scholar] [CrossRef] [PubMed]
- Drozdenko, G.; Scheel, T.; Heine, G.; Baumgrass, R.; Worm, M. Impaired T cell activation and cytokine production by calcitriol-primed human B cells. Clin. Exp. Immunol. 2014, 178, 364–372. [Google Scholar] [CrossRef] [PubMed]
- Milliken, S.V.; Wassall, H.; Lewis, B.J.; Logie, J.; Barker, R.N.; Macdonald, H.; Vickers, M.A.; Ormerod, A.D. Effects of ultraviolet light on human serum 25-hydroxyvitamin D and systemic immune function. J. Allergy Clin. Immunol. 2012, 129, 1554–1561. [Google Scholar] [CrossRef]
- Al-Zubeidi, H.; Leon-Chi, L.; Newfield, R.S. Low vitamin D level in pediatric patients with new onset type 1 diabetes is common, especially if in ketoacidosis. Pediatr. Diabetes 2016, 17, 592–598. [Google Scholar] [CrossRef]
- Savastio, S.; Cadario, F.; Genoni, G.; Bellomo, G.; Bagnati, M.; Secco, G.; Picchi, R.; Giglione, E.; Bona, G. Vitamin D Deficiency and Glycemic Status in Children and Adolescents with Type 1 Diabetes Mellitus. PLoS ONE 2016, 11, e0162554. [Google Scholar] [CrossRef] [PubMed]
- Makinen, M.; Mykkanen, J.; Koskinen, M.; Simell, V.; Veijola, R.; Hyoty, H.; Ilonen, J.; Knip, M.; Simell, O.; Toppari, J. Serum 25-Hydroxyvitamin D Concentrations in Children Progressing to Autoimmunity and Clinical Type 1 Diabetes. J. Clin. Endocrinol. Metab. 2016, 101, 723–729. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Granfors, M.; Augustin, H.; Ludvigsson, J.; Brekke, H.K. No association between use of multivitamin supplement containing vitamin D during pregnancy and risk of Type 1 Diabetes in the child. Pediatr. Diabetes 2016, 17, 525–530. [Google Scholar] [CrossRef] [PubMed]
- Wood, J.R.; Connor, C.G.; Cheng, P.; Ruedy, K.J.; Tamborlane, W.V.; Klingensmith, G.; Schatz, D.; Gregg, B.; Cengiz, E.; Willi, S.; et al. Vitamin D status in youth with type 1 and type 2 diabetes enrolled in the Pediatric Diabetes Consortium (PDC) is not worse than in youth without diabetes. Pediatr. Diabetes 2016, 17, 584–591. [Google Scholar] [CrossRef] [PubMed]
- Bland, R.; Markovic, D.; Hills, C.E.; Hughes, S.V.; Chan, S.L.; Squires, P.E.; Hewison, M. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J. Steroid Biochem. Mol. Biol. 2004, 89, 121–125. [Google Scholar] [CrossRef] [PubMed]
- Maestro, B.; Davila, N.; Carranza, M.C.; Calle, C. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J. Steroid Biochem. Mol. Biol. 2003, 84, 223–230. [Google Scholar] [CrossRef]
- El-Fakhri, N.; McDevitt, H.; Shaikh, M.G.; Halsey, C.; Ahmed, S.F. Vitamin D and its effects on glucose homeostasis, cardiovascular function and immune function. Horm. Res. Paediatr. 2014, 81, 363–378. [Google Scholar] [CrossRef]
- Bae, K.N.; Nam, H.K.; Rhie, Y.J.; Song, D.J.; Lee, K.H. Low levels of 25-hydroxyvitamin D in children and adolescents with type 1 diabetes mellitus: A single center experience. Ann. Pediatr. Endocrinol. Metab. 2018, 23, 21–27. [Google Scholar] [CrossRef]
- Federico, G.; Genoni, A.; Puggioni, A.; Saba, A.; Gallo, D.; Randazzo, E.; Salvatoni, A.; Toniolo, A. Vitamin D status, enterovirus infection, and type 1 diabetes in Italian children/adolescents. Pediatr. Diabetes 2018, 19, 923–929. [Google Scholar] [CrossRef]
- Cooper, J.D.; Smyth, D.J.; Walker, N.M.; Stevens, H.; Burren, O.S.; Wallace, C.; Greissl, C.; Ramos-Lopez, E.; Hypponen, E.; Dunger, D.B.; et al. Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 2011, 60, 1624–1631. [Google Scholar] [CrossRef]
- Sahin, O.A.; Goksen, D.; Ozpinar, A.; Serdar, M.; Onay, H. Association of vitamin D receptor polymorphisms and type 1 diabetes susceptibility in children: A meta-analysis. Endocr. Connect. 2017, 6, 159–171. [Google Scholar] [CrossRef] [PubMed]
- Kodama, K.; Zhao, Z.; Toda, K.; Yip, L.; Fuhlbrigge, R.; Miao, D.; Fathman, C.G.; Yamada, S.; Butte, A.J.; Yu, L. Expression-Based Genome-Wide Association Study Links Vitamin D-Binding Protein with Autoantigenicity in Type 1 Diabetes. Diabetes 2016, 65, 1341–1349. [Google Scholar] [CrossRef] [PubMed]
- Sorensen, I.M.; Joner, G.; Jenum, P.A.; Eskild, A.; Brunborg, C.; Torjesen, P.A.; Stene, L.C. Vitamin D-binding protein and 25-hydroxyvitamin D during pregnancy in mothers whose children later developed type 1 diabetes. Diabetes Metab. Res. Rev. 2016, 32, 883–890. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tapia, G.; Marild, K.; Dahl, S.R.; Lund-Blix, N.A.; Viken, M.K.; Lie, B.A.; Njolstad, P.R.; Joner, G.; Skrivarhaug, T.; Cohen, A.S.; et al. Maternal and Newborn Vitamin D-Binding Protein, Vitamin D Levels, Vitamin D Receptor Genotype, and Childhood Type 1 Diabetes. Diabetes Care 2019, 42, 553–559. [Google Scholar] [CrossRef] [PubMed]
- Gabbay, M.A.; Sato, M.N.; Finazzo, C.; Duarte, A.J.; Dib, S.A. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual beta-cell function in new-onset type 1 diabetes mellitus. Arch. Pediatr. Adolesc. Med. 2012, 166, 601–607. [Google Scholar] [CrossRef]
- Treiber, G.; Prietl, B.; Frohlich-Reiterer, E.; Lechner, E.; Ribitsch, A.; Fritsch, M.; Rami-Merhar, B.; Steigleder-Schweiger, C.; Graninger, W.; Borkenstein, M.; et al. Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus—A randomized clinical trial. Clin. Immunol. 2015, 161, 217–224. [Google Scholar] [CrossRef] [PubMed]
- Zipitis, C.S.; Akobeng, A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: A systematic review and meta-analysis. Arch. Dis. Child. 2008, 93, 512–517. [Google Scholar] [CrossRef] [PubMed]
- Zipitis, C.S.; Mughal, Z.M.; Clayton, P.E. Assessing the population impact of low rates of vitamin D supplementation on type 1 diabetes using a new statistical method. JRSM Open 2016, 7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ataie-Jafari, A.; Loke, S.C.; Rahmat, A.B.; Larijani, B.; Abbasi, F.; Leow, M.K.; Yassin, Z. A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes. Clin. Nutr. 2013, 32, 911–917. [Google Scholar] [CrossRef] [Green Version]
- Deda, L.; Yeshayahu, Y.; Sud, S.; Cuerden, M.; Cherney, D.Z.; Sochett, E.B.; Mahmud, F.H. Improvements in peripheral vascular function with vitamin D treatment in deficient adolescents with type 1 diabetes. Pediatr. Diabetes 2018, 19, 457–463. [Google Scholar] [CrossRef] [PubMed]
- Silvis, K.; Aronsson, C.A.; Liu, X.; Uusitalo, U.; Yang, J.; Tamura, R.; Lernmark, A.; Rewers, M.; Hagopian, W.; She, J.X.; et al. Maternal dietary supplement use and development of islet autoimmunity in the offspring: TEDDY study. Pediatr. Diabetes 2019, 20, 86–92. [Google Scholar] [CrossRef] [PubMed]
- Bizzarri, C.; Pitocco, D.; Napoli, N.; Di Stasio, E.; Maggi, D.; Manfrini, S.; Suraci, C.; Cavallo, M.G.; Cappa, M.; Ghirlanda, G.; et al. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: The IMDIAB XIII trial. Diabetes Care 2010, 33, 1962–1963. [Google Scholar] [CrossRef] [PubMed]
- Perchard, R.; Magee, L.; Whatmore, A.; Ivison, F.; Murray, P.; Stevens, A.; Mughal, M.Z.; Ehtisham, S.; Campbell, J.; Ainsworth, S.; et al. A pilot interventional study to evaluate the impact of cholecalciferol treatment on HbA1c in type 1 diabetes (T1D). Endocr. Connect. 2017, 6, 225–231. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sharma, S.; Biswal, N.; Bethou, A.; Rajappa, M.; Kumar, S.; Vinayagam, V. Does Vitamin D Supplementation Improve Glycaemic Control in Children with Type 1 Diabetes Mellitus?—A Randomized Controlled Trial. J. Clin. Diagn. Res. 2017, 11, SC15. [Google Scholar] [CrossRef] [PubMed]
- Tai, K.; Need, A.G.; Horowitz, M.; Chapman, I.M. Glucose tolerance and vitamin D: Effects of treating vitamin D deficiency. Nutrition 2008, 24, 950–956. [Google Scholar] [CrossRef] [PubMed]
- Von Hurst, P.R.; Stonehouse, W.; Coad, J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient—A randomised, placebo-controlled trial. Br. J. Nutr. 2010, 103, 549–555. [Google Scholar] [CrossRef] [PubMed]
- Grimnes, G.; Figenschau, Y.; Almas, B.; Jorde, R. Vitamin D insulin secretion, sensitivity, and lipids: Results from a case-control study and a randomized controlled trial using hyperglycemic clamp technique. Diabetes 2011, 60, 2748–2757. [Google Scholar] [CrossRef]
- Gepner, A.D.; Ramamurthy, R.; Krueger, D.C.; Korcarz, C.E.; Binkley, N.; Stein, J.H. A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS ONE 2012, 7, e36617. [Google Scholar] [CrossRef]
- Toxqui, L.; Blanco-Rojo, R.; Wright, I.; Perez-Granados, A.M.; Vaquero, M.P. Changes in blood pressure and lipid levels in young women consuming a vitamin D-fortified skimmed milk: A randomised controlled trial. Nutrients 2013, 5, 4966–4977. [Google Scholar] [CrossRef]
- Jorde, R.; Sollid, S.T.; Svartberg, J.; Schirmer, H.; Joakimsen, R.M.; Njolstad, I.; Fuskevag, O.M.; Figenschau, Y.; Hutchinson, M.Y. Vitamin D 20,000 IU per Week for Five Years Does Not Prevent Progression from Prediabetes to Diabetes. J. Clin. Endocrinol. Metab. 2016, 101, 1647–1655. [Google Scholar] [CrossRef]
- He, S.; Yu, S.; Zhou, Z.; Wang, C.; Wu, Y.; Li, W. Effect of vitamin D supplementation on fasting plasma glucose, insulin resistance and prevention of type 2 diabetes mellitus in non-diabetics: A systematic review and meta-analysis. Biomed. Rep. 2018, 8, 475–484. [Google Scholar] [CrossRef] [PubMed]
- Pittas, A.G.; Dawson-Hughes, B.; Sheehan, P.; Ware, J.H.; Knowler, W.C.; Aroda, V.R.; Brodsky, I.; Ceglia, L.; Chadha, C.; Chatterjee, R.; et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N. Engl. J. Med. 2019. [Google Scholar] [CrossRef] [PubMed]
- Belenchia, A.M.; Tosh, A.K.; Hillman, L.S.; Peterson, C.A. Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: A randomized controlled trial. Am. J. Clin. Nutr. 2013, 97, 774–781. [Google Scholar] [CrossRef] [PubMed]
- Hirschler, V.; Maccallini, G.; Sanchez, M.; Claudio, G.; Molinari, C.; Figueroa, M.; Arnada, C.; Hidalgo, M. Improvement of Apolipoprotein B in Argentine Indigenous School Children after Vitamin D Supplementation. Cardiovasc. Hematol. Agents Med. Chem. 2015, 13, 137–145. [Google Scholar] [CrossRef] [PubMed]
- Kelishadi, R.; Salek, S.; Salek, M.; Hashemipour, M.; Movahedian, M. Effects of vitamin D supplementation on insulin resistance and cardiometabolic risk factors in children with metabolic syndrome: A triple-masked controlled trial. J. Pediatr. 2014, 90, 28–34. [Google Scholar] [CrossRef] [PubMed]
- Nwosu, B.U.; Maranda, L. The effects of vitamin D supplementation on hepatic dysfunction, vitamin D status, and glycemic control in children and adolescents with vitamin D deficiency and either type 1 or type 2 diabetes mellitus. PLoS ONE 2014, 9, e99646. [Google Scholar] [CrossRef] [PubMed]
- Nader, N.S.; Aguirre Castaneda, R.; Wallace, J.; Singh, R.; Weaver, A.; Kumar, S. Effect of vitamin D3 supplementation on serum 25(OH)D, lipids and markers of insulin resistance in obese adolescents: A prospective, randomized, placebo-controlled pilot trial. Horm. Res. Paediatr. 2014, 82, 107–112. [Google Scholar] [CrossRef] [PubMed]
- Javed, A.; Vella, A.; Balagopal, P.B.; Fischer, P.R.; Weaver, A.L.; Piccinini, F.; Dalla Man, C.; Cobelli, C.; Giesler, P.D.; Laugen, J.M.; et al. Cholecalciferol supplementation does not influence beta-cell function and insulin action in obese adolescents: A prospective double-blind randomized trial. J. Nutr. 2015, 145, 284–290. [Google Scholar] [CrossRef] [PubMed]
- Hirschler, V.; Maccallini, G.; Sanchez, M.S.; Castano, L.; Molinari, C. Improvement in high-density lipoprotein cholesterol levels in argentine Indian school children after vitamin D supplementation. Horm. Res. Paediatr. 2013, 80, 335–342. [Google Scholar] [CrossRef] [PubMed]
- Javed, A.; Kullo, I.J.; Balagopal, P.B.; Kumar, S. Effect of vitamin D3 treatment on endothelial function in obese adolescents. Pediatr. Obes. 2016, 11, 279–284. [Google Scholar] [CrossRef] [PubMed]
- Ferira, A.J.; Laing, E.M.; Hausman, D.B.; Hall, D.B.; McCabe, G.P.; Martin, B.R.; Hill Gallant, K.M.; Warden, S.J.; Weaver, C.M.; Peacock, M.; et al. Vitamin D Supplementation Does Not Impact Insulin Resistance in Black and White Children. J. Clin. Endocrinol. Metab. 2016, 101, 1710–1718. [Google Scholar] [CrossRef] [PubMed]
- Sethuraman, U.; Zidan, M.A.; Hanks, L.; Bagheri, M.; Ashraf, A. Impact of vitamin D treatment on 25 hydroxy vitamin D levels and insulin homeostasis in obese African American adolescents in a randomized trial. J. Clin. Transl. Endocrinol. 2018, 12, 13–19. [Google Scholar] [CrossRef] [PubMed]
- Hernan, M.A.; Olek, M.J.; Ascherio, A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999, 53, 1711–1718. [Google Scholar] [CrossRef] [PubMed]
- Dalmay, F.; Bhalla, D.; Nicoletti, A.; Cabrera-Gomez, J.A.; Cabre, P.; Ruiz, F.; Druet-Cabanac, M.; Dumas, M.; Preux, P.M. Multiple sclerosis and solar exposure before the age of 15 years: Case-control study in Cuba, Martinique and Sicily. Mult. Scler. 2010, 16, 899–908. [Google Scholar] [CrossRef] [PubMed]
- Islam, T.; Gauderman, W.J.; Cozen, W.; Mack, T.M. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007, 69, 381–388. [Google Scholar] [CrossRef] [PubMed]
- Dwyer, T.; van der Mei, I.; Ponsonby, A.L.; Taylor, B.V.; Stankovich, J.; McKay, J.D.; Thomson, R.J.; Polanowski, A.M.; Dickinson, J.L. Melanocortin 1 receptor genotype, past environmental sun exposure, and risk of multiple sclerosis. Neurology 2008, 71, 583–589. [Google Scholar] [CrossRef] [PubMed]
- van der Mei, I.A.; Ponsonby, A.L.; Dwyer, T.; Blizzard, L.; Simmons, R.; Taylor, B.V.; Butzkueven, H.; Kilpatrick, T. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. BMJ 2003, 327, 316. [Google Scholar] [CrossRef]
- Alonso, A.; Cook, S.D.; Maghzi, A.H.; Divani, A.A. A case-control study of risk factors for multiple sclerosis in Iran. Mult. Scler. 2011, 17, 550–555. [Google Scholar] [CrossRef]
- Baarnhielm, M.; Hedstrom, A.K.; Kockum, I.; Sundqvist, E.; Gustafsson, S.A.; Hillert, J.; Olsson, T.; Alfredsson, L. Sunlight is associated with decreased multiple sclerosis risk: No interaction with human leukocyte antigen-DRB1*15. Eur. J. Neurol. 2012, 19, 955–962. [Google Scholar] [CrossRef]
- Munger, K.L.; Zhang, S.M.; O’Reilly, E.; Hernan, M.A.; Olek, M.J.; Willett, W.C.; Ascherio, A. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62, 60–65. [Google Scholar] [CrossRef]
- Munger, K.L.; Levin, L.I.; Hollis, B.W.; Howard, N.S.; Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296, 2832–2838. [Google Scholar] [CrossRef]
- Kragt, J.; van Amerongen, B.; Killestein, J.; Dijkstra, C.; Uitdehaag, B.; Polman, C.; Lips, P. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult. Scler. 2009, 15, 9–15. [Google Scholar] [CrossRef]
- Shaygannejad, V.; Golabchi, K.; Haghighi, S.; Dehghan, H.; Moshayedi, A. A Comparative Study of 25 (OH) Vitamin D Serum Levels in Patients with Multiple Sclerosis and Control Group in Isfahan, Iran. Int. J. Prev. Med. 2010, 1, 195–201. [Google Scholar]
- Soilu-Hanninen, M.; Airas, L.; Mononen, I.; Heikkila, A.; Viljanen, M.; Hanninen, A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 2005, 11, 266–271. [Google Scholar] [CrossRef]
- Graves, J.S.; Barcellos, L.F.; Krupp, L.; Belman, A.; Shao, X.; Quach, H.; Hart, J.; Chitnis, T.; Weinstock-Guttman, B.; Aaen, G.; et al. Vitamin D genes influence MS relapses in children. Mult. Scler. 2019. [Google Scholar] [CrossRef]
- Willer, C.J.; Dyment, D.A.; Sadovnick, A.D.; Rothwell, P.M.; Murray, T.J.; Ebers, G.C. Timing of birth and risk of multiple sclerosis: Population based study. BMJ 2005, 330, 120. [Google Scholar] [CrossRef]
- Staples, J.; Ponsonby, A.L.; Lim, L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: Longitudinal analysis. BMJ 2010, 340, c1640. [Google Scholar]
- Torkildsen, O.; Grytten, N.; Aarseth, J.; Myhr, K.M.; Kampman, M.T. Month of birth as a risk factor for multiple sclerosis: An update. Acta Neurol. Scand. Suppl. 2012, 126, 58–62. [Google Scholar] [CrossRef]
- Disanto, G.; Morahan, J.M.; Ramagopalan, S.V. Multiple sclerosis: Risk factors and their interactions. CNS Neurol. Disord. Drug Targets 2012, 11, 545–555. [Google Scholar] [CrossRef]
- Mirzaei, F.; Michels, K.B.; Munger, K.; O’Reilly, E.; Chitnis, T.; Forman, M.R.; Giovannucci, E.; Rosner, B.; Ascherio, A. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann. Neurol. 2011, 70, 30–40. [Google Scholar] [CrossRef]
- McKay, K.A.; Jahanfar, S.; Duggan, T.; Tkachuk, S.; Tremlett, H. Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. Neurotoxicology 2016, 61, 189–212. [Google Scholar] [CrossRef]
- McLaughlin, L.; Clarke, L.; Khalilidehkordi, E.; Butzkueven, H.; Taylor, B.; Broadley, S.A. Vitamin D for the treatment of multiple sclerosis: A meta-analysis. J. Neurol. 2018, 265, 2893–2905. [Google Scholar] [CrossRef]
- Soilu-Hanninen, M.; Aivo, J.; Lindstrom, B.M.; Elovaara, I.; Sumelahti, M.L.; Farkkila, M.; Tienari, P.; Atula, S.; Sarasoja, T.; Herrala, L.; et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2012, 83, 565–571. [Google Scholar] [CrossRef]
- Lee, Y.H.; Bae, S.C. Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: A meta-analysis. Clin. Exp. Rheumatol. 2016, 34, 827–833. [Google Scholar]
- Son, K.M.; Song, S.H.; Lim, S.K.; Seo, Y.I.; Kim, H.A. Characteristics of patients with rheumatoid arthritis in clinical remission: The many aspects of DAS28 remission. Clin. Exp. Rheumatol. 2012, 30, 947–950. [Google Scholar]
- Song, G.G.; Bae, S.C.; Lee, Y.H. Association between vitamin D intake and the risk of rheumatoid arthritis: A meta-analysis. Clin. Rheumatol. 2012, 31, 1733–1739. [Google Scholar] [CrossRef]
- Lin, J.; Liu, J.; Davies, M.L.; Chen, W. Serum Vitamin D Level and Rheumatoid Arthritis Disease Activity: Review and Meta-Analysis. PLoS ONE 2016, 11, e0146351. [Google Scholar] [CrossRef]
- Wang, Y.; Zhang, F.; Wang, S.; Shang, X.; Luo, S.; Zhou, H.; Shi, H.; Cai, L. Serum Vitamin D Level is Inversely Associated with Anti-Cyclic Citrullinated Peptide Antibody Level and Disease Activity in Rheumatoid Arthritis Patients. Arch. Rheumatol. 2016, 31, 64–70. [Google Scholar] [CrossRef]
- Zakeri, Z.; Sandoughi, M.; Mashhadi, M.A.; Raeesi, V.; Shahbakhsh, S. Serum vitamin D level and disease activity in patients with recent onset rheumatoid arthritis. Int. J. Rheum. Dis. 2016, 19, 343–347. [Google Scholar] [CrossRef]
- Tizaoui, K.; Hamzaoui, K. Association between VDR polymorphisms and rheumatoid arthritis disease: Systematic review and updated meta-analysis of case-control studies. Immunobiology 2015, 220, 807–816. [Google Scholar] [CrossRef]
- Song, G.G.; Bae, S.C.; Lee, Y.H. Vitamin D receptor FokI, BsmI, and TaqI polymorphisms and susceptibility to rheumatoid arthritis: A meta-analysis. Z. Rheumatol. 2016, 75, 322–329. [Google Scholar] [CrossRef]
- Merlino, L.A.; Curtis, J.; Mikuls, T.R.; Cerhan, J.R.; Criswell, L.A.; Saag, K.G. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women’s Health Study. Arthritis Rheum. 2004, 50, 72–77. [Google Scholar] [CrossRef]
- Chandrashekara, S.; Patted, A. Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: An exploratory study. Int. J. Rheum. Dis. 2015, 20, 825–831. [Google Scholar] [CrossRef]
- Franco, A.S.; Freitas, T.Q.; Bernardo, W.M.; Pereira, R.M.R. Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: A systematic review and meta-analysis. Medicine 2017, 96, e7024. [Google Scholar] [CrossRef] [PubMed]
- Gardner, D.H.; Jeffery, L.E.; Soskic, B.; Briggs, Z.; Hou, T.Z.; Raza, K.; Sansom, D.M. 1,25(OH)2D3 Promotes the Efficacy of CD28 Costimulation Blockade by Abatacept. J. Immunol. 2015, 195, 2657–2665. [Google Scholar] [CrossRef]
- Amital, H.; Szekanecz, Z.; Szucs, G.; Danko, K.; Nagy, E.; Csepany, T.; Kiss, E.; Rovensky, J.; Tuchynova, A.; Kozakova, D.; et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: Is it time to routinely supplement patients with SLE with vitamin D? Ann. Rheum. Dis. 2010, 69, 1155–1157. [Google Scholar] [CrossRef]
- Robinson, A.B.; Thierry-Palmer, M.; Gibson, K.L.; Rabinovich, C.E. Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. J. Pediatr. 2012, 160, 297–302. [Google Scholar] [CrossRef]
- Wright, T.B.; Shults, J.; Leonard, M.B.; Zemel, B.S.; Burnham, J.M. Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J. Pediatr. 2009, 155, 260–265. [Google Scholar] [CrossRef]
- Kamen, D.; Aranow, C. Vitamin D in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2008, 20, 532–537. [Google Scholar] [CrossRef]
- AlSaleem, A.; AlE’ed, A.; AlSaghier, A.; Al-Mayouf, S.M. Vitamin D status in children with systemic lupus erythematosus and its association with clinical and laboratory parameters. Clin. Rheumatol. 2015, 34, 81–84. [Google Scholar] [CrossRef]
- Borba, V.Z.; Vieira, J.G.; Kasamatsu, T.; Radominski, S.C.; Sato, E.I.; Lazaretti-Castro, M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos. Int. 2009, 20, 427–433. [Google Scholar] [CrossRef] [PubMed]
- Schneider, L.; Dos Santos, A.S.; Santos, M.; da Silva Chakr, R.M.; Monticielo, O.A. Vitamin D and systemic lupus erythematosus: State of the art. Clin. Rheumatol. 2014, 33, 1033–1038. [Google Scholar] [CrossRef] [PubMed]
- Lima, G.L.; Paupitz, J.; Aikawa, N.E.; Takayama, L.; Bonfa, E.; Pereira, R.M. Vitamin D Supplementation in Adolescents and Young Adults with Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Care Res. 2016, 68, 91–98. [Google Scholar] [CrossRef] [PubMed]
- Abou-Raya, A.; Abou-Raya, S.; Helmii, M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: A randomized placebo-controlled trial. J. Rheumatol. 2013, 40, 265–272. [Google Scholar] [CrossRef] [PubMed]
- Terrier, B.; Derian, N.; Schoindre, Y.; Chaara, W.; Geri, G.; Zahr, N.; Mariampillai, K.; Rosenzwajg, M.; Carpentier, W.; Musset, L.; et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res. Ther. 2012, 14, R221. [Google Scholar] [CrossRef] [PubMed]
- Shoenfeld, Y.; Giacomelli, R.; Azrielant, S.; Berardicurti, O.; Reynolds, J.A.; Bruce, I.N. Vitamin D and systemic lupus erythematosus—The hype and the hope. Autoimmun. Rev. 2018, 17, 19–23. [Google Scholar] [CrossRef] [PubMed]
- Smith, E.L.; Walworth, N.C.; Holick, M.F. Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J. Investig. Dermatol. 1986, 86, 709–714. [Google Scholar] [CrossRef] [PubMed]
- Smith, E.L.; Pincus, S.H.; Donovan, L.; Holick, M.F. A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis. J. Am. Acad. Dermatol. 1988, 19, 516–528. [Google Scholar] [CrossRef]
- Stefanic, M.; Rucevic, I.; Barisic-Drusko, V. Meta-analysis of vitamin D receptor polymorphisms and psoriasis risk. Int. J. Dermatol. 2013, 52, 705–710. [Google Scholar] [CrossRef]
- Lee, Y.H. Vitamin D receptor ApaI, TaqI, BsmI, and FokI polymorphisms and psoriasis susceptibility: An updated meta-analysis. Clin. Exp. Dermatol. 2019, 44, 498–505. [Google Scholar] [CrossRef]
- Saleky, S.; Bulur, I.; Saracoglu, Z.N. Narrowband UVB treatment increases serum 25-hydroxyvitamin D levels in patients with chronic plaque psoriasis. Cutis 2017, 99, 431–435. [Google Scholar] [PubMed]
- Gupta, A.; Arora, T.C.; Jindal, A.; Bhadoria, A.S. Efficacy of narrowband ultraviolet B phototherapy and levels of serum vitamin D3 in psoriasis: A prospective study. Indian Dermatol. Online J. 2016, 7, 87–92. [Google Scholar] [CrossRef] [PubMed]
- Disphanurat, W.; Viarasilpa, W.; Chakkavittumrong, P.; Pongcharoen, P. The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study. Dermatol. Res. Pract. 2019, 2019. [Google Scholar] [CrossRef] [PubMed]
- Del Rosso, J.Q.; Kircik, L.H. The Effect of Calcipotriene-Betamethasone Dipropionate Aerosol Foam versus Vehicle on Target Lesions in Moderate Severity Plaque Psoriasis: Focus on Elbows and Knees. J. Drugs Dermatol. 2019, 18, 358–361. [Google Scholar] [PubMed]
- German, B.; Wei, R.; Hener, P.; Martins, C.; Ye, T.; Gottwick, C.; Yang, J.; Seneschal, J.; Boniface, K.; Li, M. Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. JCI Insight. 2019, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hau, C.S.; Shimizu, T.; Tada, Y.; Kamata, M.; Takeoka, S.; Shibata, S.; Mitsui, A.; Asano, Y.; Sugaya, M.; Kadono, T.; et al. The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production. J. Dermatol. Sci. 2018, 92, 117–126. [Google Scholar] [CrossRef] [PubMed]
- Cantorna, M.T.; Munsick, C.; Bemiss, C.; Mahon, B.D. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J. Nutr. 2000, 130, 2648–2652. [Google Scholar] [CrossRef]
- Bouillon, R.; Carmeliet, G.; Verlinden, L.; van Etten, E.; Verstuyf, A.; Luderer, H.F.; Lieben, L.; Mathieu, C.; Demay, M. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr. Rev. 2008, 29, 726–776. [Google Scholar] [CrossRef]
- Simmons, J.D.; Mullighan, C.; Welsh, K.I.; Jewell, D.P. Vitamin D receptor gene polymorphism: Association with Crohn’s disease susceptibility. Gut 2000, 47, 211–214. [Google Scholar] [CrossRef]
- Wang, L.; Wang, Z.T.; Hu, J.J.; Fan, R.; Zhou, J.; Zhong, J. Polymorphisms of the vitamin D receptor gene and the risk of inflammatory bowel disease: A meta-analysis. Genet. Mol. Res. 2014, 13, 2598–2610. [Google Scholar] [CrossRef]
- Peyrin-Biroulet, L.; Oussalah, A.; Boucekkine, T.; Bigard, M.A. TNF antagonists in the treatment of inflammatory bowel disease: Results of a survey of gastroenterologists in the French region of Lorraine. Gastroenterol. Clin. Biol. 2009, 33, 23–30. [Google Scholar] [CrossRef] [PubMed]
- Janssen, C.E.; Globig, A.M.; Busse Grawitz, A.; Bettinger, D.; Hasselblatt, P. Seasonal variability of vitamin D status in patients with inflammatory bowel disease—A retrospective cohort study. PLoS ONE 2019, 14, e0217238. [Google Scholar] [CrossRef] [PubMed]
- Lu, C.; Yang, J.; Yu, W.; Li, D.; Xiang, Z.; Lin, Y.; Yu, C. Association between 25(OH)D Level, Ultraviolet Exposure, Geographical Location, and Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. PLoS ONE 2015, 10, e0132036. [Google Scholar] [CrossRef] [PubMed]
- Del Pinto, R.; Pietropaoli, D.; Chandar, A.K.; Ferri, C.; Cominelli, F. Association between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic Review and Meta-analysis. Inflamm. Bowel Dis. 2015, 21, 2708–2717. [Google Scholar] [CrossRef] [PubMed]
- Pappa, H.M.; Mitchell, P.D.; Jiang, H.; Kassiff, S.; Filip-Dhima, R.; DiFabio, D.; Quinn, N.; Lawton, R.C.; Bronzwaer, M.E.; Koenen, M.; et al. Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: A randomized clinical trial comparing two regimens. J. Clin. Endocrinol. Metab. 2014, 99, 3408–3417. [Google Scholar] [CrossRef]
- Schardey, J.; Globig, A.M.; Janssen, C.; Hofmann, M.; Manegold, P.; Thimme, R.; Hasselblatt, P. Vitamin D inhibits pro-inflammatory T cell function in patients with inflammatory bowel disease. J. Crohn’s Colitis 2019. [Google Scholar] [CrossRef] [PubMed]
- Guo, H.; Zheng, Y.; Cai, X.; Yang, H.; Zhang, Y.; Hao, L.; Jin, Y.; Yang, G. Correlation between serum vitamin D status and immunological changes in children affected by gastrointestinal food allergy. Allergol. Immunopathol. 2018, 46, 39–44. [Google Scholar] [CrossRef]
- Hennessy, A.; Hourihane, J.O.; Malvisi, L.; Irvine, A.D.; Kenny, L.C.; Murray, D.M.; Kiely, M.E. Antenatal vitamin D exposure and childhood eczema, food allergy, asthma and allergic rhinitis at 2 and 5 years of age in the atopic disease-specific Cork BASELINE Birth Cohort Study. Allergy 2018, 73, 2182–2191. [Google Scholar] [CrossRef]
- Molloy, J.; Koplin, J.J.; Allen, K.J.; Tang, M.L.K.; Collier, F.; Carlin, J.B.; Saffery, R.; Burgner, D.; Ranganathan, S.; Dwyer, T.; et al. Vitamin D insufficiency in the first 6 months of infancy and challenge-proven IgE-mediated food allergy at 1 year of age: A case-cohort study. Allergy 2017, 72, 1222–1231. [Google Scholar] [CrossRef]
- Willits, E.K.; Wang, Z.; Jin, J.; Patel, B.; Motosue, M.; Bhagia, A.; Almasri, J.; Erwin, P.J.; Kumar, S.; Joshi, A.Y. Vitamin D and food allergies in children: A systematic review and meta-analysis. Allergy Asthma Proc. 2017, 38, 21–28. [Google Scholar] [CrossRef]
- Peroni, D.G.; Boner, A.L. Food allergy: The perspectives of prevention using vitamin, D. Curr. Opin. Allergy Clin. Immunol. 2013, 13, 287–292. [Google Scholar] [CrossRef] [PubMed]
- Rosendahl, J.; Pelkonen, A.S.; Helve, O.; Hauta-Alus, H.; Holmlund-Suila, E.; Valkama, S.; Enlund-Cerullo, M.; Viljakainen, H.; Hytinantti, T.; Makitie, O.; et al. High-Dose Vitamin D Supplementation Does Not Prevent Allergic Sensitization of Infants. J. Pediatr. 2019, 209, 139–145.e1. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Suneetha, P.V.; Sarin, S.K.; Goyal, A.; Kumar, G.T.; Shukla, D.K.; Hissar, S. Association between vitamin D receptor, CCR5, TNF-alpha and TNF-beta gene polymorphisms and HBV infection and severity of liver disease. J. Hepatol. 2006, 44, 856–863. [Google Scholar] [CrossRef] [PubMed]
- Nosratabadi, R.; Arababadi, M.K.; Salehabad, V.A.; Shamsizadeh, A.; Mahmoodi, M.; Sayadi, A.R.; Kennedy, D. Polymorphisms within exon 9 but not intron 8 of the vitamin D receptor are associated with the nephropathic complication of type-2 diabetes. Int. J. Immunogenet. 2010, 37, 493–497. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hu, Y.C.; Wang, W.W.; Jiang, W.Y.; Li, C.Q.; Guo, J.C.; Xun, Y.H. Low vitamin D levels are associated with high viral loads in patients with chronic hepatitis B: A systematic review and meta-analysis. BMC Gastroenterol. 2019, 19, 84. [Google Scholar] [CrossRef] [PubMed]
- Petta, S.; Camma, C.; Scazzone, C.; Tripodo, C.; Di Marco, V.; Bono, A.; Cabibi, D.; Licata, G.; Porcasi, R.; Marchesini, G.; et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis, C. Hepatology 2010, 51, 1158–1167. [Google Scholar] [CrossRef]
- Barooah, P.; Saikia, S.; Bharadwaj, R.; Sarmah, P.; Bhattacharyya, M.; Goswami, B.; Medhi, S. Role of VDR, GC, and CYP2R1 Polymorphisms in the Development of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients. Genet. Test. Mol. Biomark. 2019, 23, 325–331. [Google Scholar] [CrossRef]
- Murayama, A.; Saitoh, H.; Takeuchi, A.; Yamada, N.; Matsumura, T.; Shiina, M.; Muramatsu, M.; Wakita, T.; Imawari, M.; Kato, T. Vitamin D derivatives inhibit hepatitis C virus production through the suppression of apolipoprotein. Antivir. Res. 2018, 160, 55–63. [Google Scholar] [CrossRef]
- Bitetto, D.; Fabris, C.; Fornasiere, E.; Pipan, C.; Fumolo, E.; Cussigh, A.; Bignulin, S.; Cmet, S.; Fontanini, E.; Falleti, E.; et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl. Int. 2011, 24, 43–50. [Google Scholar] [CrossRef]
- Komolmit, P.; Kimtrakool, S.; Suksawatamnuay, S.; Thanapirom, K.; Chattrasophon, K.; Thaimai, P.; Chirathaworn, C.; Poovorawan, Y. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: A randomized, double-blind, placebo-controlled study. Sci. Rep. 2017, 7, 8905. [Google Scholar] [CrossRef]
- Hall, S.C.; Agrawal, D.K. Vitamin D and Bronchial Asthma: An Overview of Data from the Past 5 Years. Clin. Ther. 2017, 39, 917–929. [Google Scholar] [CrossRef]
- Reinehr, T.; Schnabel, D.; Wabitsch, M.; Bechtold-Dalla Pozza, S.; Buhrer, C.; Heidtmann, B.; Jochum, F.; Kauth, T.; Korner, A.; Mihatsch, W.; et al. Vitamin D supplementation after the second year of life: Joint position of the Committee on Nutrition, German Society for Pediatric and Adolescent Medicine (DGKJ e.V.), and the German Society for Pediatric Endocrinology and Diabetology (DGKED e.V.). Mol. Cell. Pediatr. 2019, 6, 3. [Google Scholar] [CrossRef] [PubMed]
- Jolliffe, D.A.; Greenberg, L.; Hooper, R.L.; Griffiths, C.J.; Camargo, C.A., Jr.; Kerley, C.P.; Jensen, M.E.; Mauger, D.; Stelmach, I.; Urashima, M.; et al. Vitamin D supplementation to prevent asthma exacerbations: A systematic review and meta-analysis of individual participant data. Lancet Respir. Med. 2017, 5, 881–890. [Google Scholar] [CrossRef]
- Martineau, A.R.; Cates, C.J.; Urashima, M.; Jensen, M.; Griffiths, A.P.; Nurmatov, U.; Sheikh, A.; Griffiths, C.J. Vitamin D for the management of asthma. Cochrane Database Syst. Rev. 2016, 9, CD011511. [Google Scholar] [CrossRef] [PubMed]
- Urashima, M.; Segawa, T.; Okazaki, M.; Kurihara, M.; Wada, Y.; Ida, H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am. J. Clin. Nutr. 2010, 91, 1255–1260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Urashima, M.; Mezawa, H.; Noya, M.; Camargo, C.A., Jr. Effects of vitamin D supplements on influenza A illness during the 2009 H1N1 pandemic: A randomized controlled trial. Food Funct. 2014, 5, 2365–2370. [Google Scholar] [CrossRef] [PubMed]
- Martineau, A.R.; Jolliffe, D.A.; Hooper, R.L.; Greenberg, L.; Aloia, J.F.; Bergman, P.; Dubnov-Raz, G.; Esposito, S.; Ganmaa, D.; Ginde, A.A.; et al. Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data. BMJ 2017, 356, i6583. [Google Scholar] [CrossRef] [PubMed]
- Martineau, A.R.; Jolliffe, D.A.; Greenberg, L.; Aloia, J.F.; Bergman, P.; Dubnov-Raz, G.; Esposito, S.; Ganmaa, D.; Ginde, A.A.; Goodall, E.C.; et al. Vitamin D supplementation to prevent acute respiratory infections: Individual participant data meta-analysis. Health Technol. Assess. 2019, 23, 1–44. [Google Scholar] [CrossRef] [PubMed]
- Yakoob, M.Y.; Salam, R.A.; Khan, F.R.; Bhutta, Z.A. Vitamin D supplementation for preventing infections in children under five years of age. Cochrane Database Syst. Rev. 2016, 11, CD008824. [Google Scholar] [CrossRef]
- Aglipay, M.; Birken, C.S.; Parkin, P.C.; Loeb, M.B.; Thorpe, K.; Chen, Y.; Laupacis, A.; Mamdani, M.; Macarthur, C.; Hoch, J.S.; et al. Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children. JAMA 2017, 318, 245–254. [Google Scholar] [CrossRef]
- Correa-Rodriguez, M.; Carrillo-Avila, J.A.; Schmidt-RioValle, J.; Gonzalez-Jimenez, E.; Vargas, S.; Martin, J.; Rueda-Medina, B. Genetic association analysis of vitamin D receptor gene polymorphisms and obesity-related phenotypes. Gene 2018, 640, 51–56. [Google Scholar] [CrossRef]
- Olson, M.L.; Maalouf, N.M.; Oden, J.D.; White, P.C.; Hutchison, M.R. Vitamin D deficiency in obese children and its relationship to glucose homeostasis. J. Clin. Endocrinol. Metab. 2012, 97, 279–285. [Google Scholar] [CrossRef]
- Smotkin-Tangorra, M.; Purushothaman, R.; Gupta, A.; Nejati, G.; Anhalt, H.; Ten, S. Prevalence of vitamin D insufficiency in obese children and adolescents. J. Pediatr. Endocrinol. Metab. 2007, 20, 817–823. [Google Scholar] [CrossRef] [PubMed]
- Nsiah-Kumi, P.A.; Erickson, J.M.; Beals, J.L.; Ogle, E.A.; Whiting, M.; Brushbreaker, C.; Borgeson, C.D.; Qiu, F.; Yu, F.; Larsen, J.L. Vitamin D insufficiency is associated with diabetes risk in Native American children. Clin. Pediatr. 2012, 51, 146–153. [Google Scholar] [CrossRef] [PubMed]
- Roth, C.L.; Elfers, C.; Kratz, M.; Hoofnagle, A.N. Vitamin d deficiency in obese children and its relationship to insulin resistance and adipokines. J. Obes. 2011, 2011, 495101. [Google Scholar] [CrossRef] [PubMed]
- Poomthavorn, P.; Saowan, S.; Mahachoklertwattana, P.; Chailurkit, L.; Khlairit, P. Vitamin D status and glucose homeostasis in obese children and adolescents living in the tropics. Int. J. Obes. 2012, 36, 491–495. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bril, F.; Maximos, M.; Portillo-Sanchez, P.; Biernacki, D.; Lomonaco, R.; Subbarayan, S.; Correa, M.; Lo, M.; Suman, A.; Cusi, K. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. J. Hepatol. 2015, 62, 405–411. [Google Scholar] [CrossRef]
- Liu, D.; Fernandez, B.O.; Hamilton, A.; Lang, N.N.; Gallagher, J.M.C.; Newby, D.E.; Feelisch, M.; Weller, R.B. UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure independently of nitric oxide synthase. J. Investig. Dermatol. 2014, 134, 1839–1846. [Google Scholar] [CrossRef]
- Tangpricha, V.; Flanagan, J.N.; Whitlatch, L.W.; Tseng, C.C.; Chen, T.C.; Holt, P.R.; Lipkin, M.S.; Holick, M.F. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 2001, 357, 1673–1674. [Google Scholar] [CrossRef]
- Mawer, E.B.; Hayes, M.E.; Heys, S.E.; Davies, M.; White, A.; Stewart, M.F.; Smith, G.N. Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line. J. Clin. Endocrinol. Metab. 1994, 79, 554–560. [Google Scholar] [PubMed]
- Cross, H.S.; Bareis, P.; Hofer, H.; Bischof, M.G.; Bajna, E.; Kriwanek, S.; Bonner, E.; Peterlik, M. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001, 66, 287–292. [Google Scholar] [CrossRef]
- Fouda, A.; Kandil, S.; Boujettif, K.; Fayea, N. Hypovitamininosis D in Childhood Cancer Survivors: Importance of Vitamin D Supplementation and Measurement Over Different Points of Time. J. Pediatr. Hematol. Oncol. 2018, 40, e83–e90. [Google Scholar] [CrossRef] [PubMed]
- Demirsoy, U.; Sarper, N.; Aylan Gelen, S.; Zengin, E.; Kum, T.; Demir, H. The Association of Oral Vitamin D and Calcium Supplementation with Bone Mineral Density in Pediatric Acute Lymphoblastic Leukemia Patients. J. Pediatr. Hematol. Oncol. 2017, 39, 287–292. [Google Scholar] [CrossRef] [PubMed]
- Genc, D.B.; Vural, S.; Yagar, G. The Incidence of and Factors Associated with Vitamin D Deficiency in Newly Diagnosed Children with Cancer. Nutr. Cancer 2016, 68, 756–761. [Google Scholar] [CrossRef] [PubMed]
- Williams, J.D.; Aggarwal, A.; Swami, S.; Krishnan, A.V.; Ji, L.; Albertelli, M.A.; Feldman, B.J. Tumor Autonomous Effects of Vitamin D Deficiency Promote Breast Cancer Metastasis. Endocrinology 2016, 157, 1341–1347. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grant, W.B. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 2002, 94, 272–281. [Google Scholar] [CrossRef] [PubMed]
- Bodiwala, D.; Luscombe, C.J.; French, M.E.; Liu, S.; Saxby, M.F.; Jones, P.W.; Ramachandran, S.; Fryer, A.A.; Strange, R.C. Susceptibility to prostate cancer: Studies on interactions between UVR exposure and skin type. Carcinogenesis 2003, 24, 711–717. [Google Scholar] [CrossRef] [PubMed]
- Pritchard, R.S.; Baron, J.A.; de Verdier, M.G. Dietary calcium, vitamin, D.; and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol. Biomark. Prev. 1996, 5, 897–900. [Google Scholar]
- Gandini, S.; Gnagnarella, P.; Serrano, D.; Pasquali, E.; Raimondi, S. Vitamin D receptor polymorphisms and cancer. Adv. Exp. Med. Biol. 2014, 810, 69–105. [Google Scholar]
- Kazemian, E.; Akbari, M.E.; Moradi, N.; Gharibzadeh, S.; Mondul, A.M.; Jamshidi-Naeini, Y.; Khademolmele, M.; Zarins, K.R.; Ghodoosi, N.; Amouzegar, A.; et al. Vitamin D Receptor Genetic Variation and Cancer Biomarkers among Breast Cancer Patients Supplemented with Vitamin D3: A Single-Arm Non-Randomized Before and After Trial. Nutrients 2019, 11, 1264. [Google Scholar] [CrossRef]
- Jacobs, E.T.; Kohler, L.N.; Kunihiro, A.G.; Jurutka, P.W. Vitamin D and Colorectal, Breast, and Prostate Cancers: A Review of the Epidemiological Evidence. J. Cancer 2016, 7, 232–240. [Google Scholar] [CrossRef] [PubMed]
- Yin, L.; Grandi, N.; Raum, E.; Haug, U.; Arndt, V.; Brenner, H. Meta-analysis: Serum vitamin D and breast cancer risk. Eur. J. Cancer 2010, 46, 2196–2205. [Google Scholar] [CrossRef] [PubMed]
- Kim, Y.; Je, Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: A meta-analysis. Br. J. Cancer 2014, 110, 2772–2784. [Google Scholar] [CrossRef] [PubMed]
- Gandini, S.; Boniol, M.; Haukka, J.; Byrnes, G.; Cox, B.; Sneyd, M.J.; Mullie, P.; Autier, P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer 2011, 128, 1414–1424. [Google Scholar] [CrossRef] [PubMed]
- Deschasaux, M.; Souberbielle, J.C.; Latino-Martel, P.; Sutton, A.; Charnaux, N.; Druesne-Pecollo, N.; Galan, P.; Hercberg, S.; Le Clerc, S.; Kesse-Guyot, E.; et al. Weight Status and Alcohol Intake Modify the Association between Vitamin D and Breast Cancer Risk. J. Nutr. 2016, 146, 576–585. [Google Scholar] [CrossRef] [Green Version]
- Chlebowski, R.T.; Johnson, K.C.; Kooperberg, C.; Pettinger, M.; Wactawski-Wende, J.; Rohan, T.; Rossouw, J.; Lane, D.; O’Sullivan, M.J.; Yasmeen, S.; et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J. Natl. Cancer Inst. 2008, 100, 1581–1591. [Google Scholar] [CrossRef]
- Cadeau, C.; Fournier, A.; Mesrine, S.; Clavel-Chapelon, F.; Fagherazzi, G.; Boutron-Ruault, M.C. Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: Evidence from the E3N cohort. Am. J. Clin. Nutr. 2015, 102, 966–973. [Google Scholar] [CrossRef]
- Madden, J.M.; Murphy, L.; Zgaga, L.; Bennett, K. De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival. Breast Cancer Res. Treat. 2018, 172, 179–190. [Google Scholar] [CrossRef]
- Crew, K.D.; Anderson, G.L.; Hershman, D.L.; Terry, M.B.; Tehranifar, P.; Lew, D.L.; Yee, M.; Brown, E.A.; Kairouz, S.S.; Kuwajerwala, N.; et al. Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prev. Res. 2019. [Google Scholar] [CrossRef]
- Manson, J.E.; Cook, N.R.; Lee, I.M.; Christen, W.; Bassuk, S.S.; Mora, S.; Gibson, H.; Gordon, D.; Copeland, T.; D’Agostino, D.; et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N. Engl. J. Med. 2019, 380, 33–44. [Google Scholar] [CrossRef]
- Yin, L.; Grandi, N.; Raum, E.; Haug, U.; Arndt, V.; Brenner, H. Meta-analysis: Serum vitamin D and colorectal adenoma risk. Prev. Med. 2011, 53, 10–16. [Google Scholar] [CrossRef] [PubMed]
- Wei, M.Y.; Garland, C.F.; Gorham, E.D.; Mohr, S.B.; Giovannucci, E. Vitamin D and prevention of colorectal adenoma: A meta-analysis. Cancer Epidemiol. Biomark. Prev. 2008, 17, 2958–2969. [Google Scholar] [CrossRef] [PubMed]
- Jacobs, E.T.; Hibler, E.A.; Lance, P.; Sardo, C.L.; Jurutka, P.W. Association between circulating concentrations of 25(OH)D and colorectal adenoma: A pooled analysis. Int. J. Cancer 2013, 133, 2980–2988. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garland, C.F.; Gorham, E.D. Dose-response of serum 25-hydroxyvitamin D in association with risk of colorectal cancer: A meta-analysis. J. Steroid Biochem. Mol. Biol. 2017, 168, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Ma, Y.; Zhang, P.; Wang, F.; Yang, J.; Liu, Z.; Qin, H. Association between vitamin D and risk of colorectal cancer: A systematic review of prospective studies. J. Clin. Oncol. 2011, 29, 3775–3782. [Google Scholar] [CrossRef] [PubMed]
- Sheng, S.; Chen, Y.; Shen, Z. Correlation between polymorphism of vitamin D receptor TaqI and susceptibility to colorectal cancer: A meta-analysis. Medicine 2017, 96, e7242. [Google Scholar] [CrossRef] [PubMed]
- He, Y.; Timofeeva, M.; Farrington, S.M.; Vaughan-Shaw, P.; Svinti, V.; Walker, M.; Zgaga, L.; Meng, X.; Li, X.; Spiliopoulou, A.; et al. Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: A large Mendelian randomisation study. BMC Med. 2018, 16, 142. [Google Scholar] [CrossRef]
- Grau, M.V.; Baron, J.A.; Sandler, R.S.; Haile, R.W.; Beach, M.L.; Church, T.R.; Heber, D. Vitamin D calcium supplementation, and colorectal adenomas: Results of a randomized trial. J. Natl. Cancer Inst. 2003, 95, 1765–1771. [Google Scholar] [CrossRef]
- Gao, Y.; Um, C.Y.; Fedirko, V.; Rutherford, R.E.; Seabrook, M.E.; Barry, E.L.; Baron, J.A.; Bostick, R.M. Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients. PLoS ONE 2018, 13, e0208762. [Google Scholar] [CrossRef]
- Horvath, H.C.; Lakatos, P.; Kosa, J.P.; Bacsi, K.; Borka, K.; Bises, G.; Nittke, T.; Hershberger, P.A.; Speer, G.; Kallay, E. The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J. Histochem. Cytochem. 2010, 58, 277–285. [Google Scholar] [CrossRef]
- Wactawski-Wende, J.; Kotchen, J.M.; Anderson, G.L.; Assaf, A.R.; Brunner, R.L.; O’Sullivan, M.J.; Margolis, K.L.; Ockene, J.K.; Phillips, L.; Pottern, L.; et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 2006, 354, 684–696. [Google Scholar] [CrossRef] [PubMed]
- Autier, P.; Mullie, P.; Macacu, A.; Dragomir, M.; Boniol, M.; Coppens, K.; Pizot, C. Effect of vitamin D supplementation on non-skeletal disorders: A systematic review of meta-analyses and randomised trials. Lancet Diabetes Endocrinol. 2017, 5, 986–1004. [Google Scholar] [CrossRef]
- Calderwood, A.H.; Baron, J.A.; Mott, L.A.; Ahnen, D.J.; Bostick, R.M.; Figueiredo, J.C.; Passarelli, M.N.; Rees, J.R.; Robertson, D.J.; Barry, E.L. No Evidence for Posttreatment Effects of Vitamin D and Calcium Supplementation on Risk of Colorectal Adenomas in a Randomized Trial. Cancer Prev. Res. 2019, 12, 295–304. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baron, J.A.; Barry, E.L.; Ivanova, A. Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N. Engl. J. Med. 2016, 374, 791–792. [Google Scholar] [CrossRef] [PubMed]
- Urashima, M.; Ohdaira, H.; Akutsu, T.; Okada, S.; Yoshida, M.; Kitajima, M.; Suzuki, Y. Effect of Vitamin D Supplementation on Relapse-Free Survival among Patients with Digestive Tract Cancers: The AMATERASU Randomized Clinical Trial. JAMA 2019, 321, 1361–1369. [Google Scholar] [CrossRef] [PubMed]
- Ng, K.; Nimeiri, H.S.; McCleary, N.J.; Abrams, T.A.; Yurgelun, M.B.; Cleary, J.M.; Rubinson, D.A.; Schrag, D.; Miksad, R.; Bullock, A.J.; et al. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival among Patients with Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA 2019, 321, 1370–1379. [Google Scholar] [CrossRef] [PubMed]
- Tuohimaa, P.; Tenkanen, L.; Ahonen, M.; Lumme, S.; Jellum, E.; Hallmans, G.; Stattin, P.; Harvei, S.; Hakulinen, T.; Luostarinen, T.; et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer 2004, 108, 104–108. [Google Scholar] [CrossRef] [PubMed]
- Petrou, S.; Mamais, I.; Lavranos, G.; Tzanetakou, P.T.; Chrysostomou, S. Effect of Vitamin D Supplementation in Prostate Cancer: A Systematic Review of Randomized Control Trials. Int. J. Vitam. Nutr. Res. 2018, 88, 100–112. [Google Scholar] [CrossRef] [PubMed]
Reference | Type of Study | Intervention | Participants | Results (Intervention) |
---|---|---|---|---|
Type 1 Diabetes | ||||
Studies examining effects on immune modulation | ||||
[25] | 18-month randomized controlled trial (RCT) | 2000 IUs vitamin D3 daily or placebo | 38 participants; 35 completers; 7–30 years old | Increase in regulatory T-cell (T-reg) percentage; lower cumulative incidence of progression to undetectable C-peptide; no difference in HbA1C, insulin requirement or BMI |
[26] | 12-month RCT | 70 IUs/kg/day vitamin D3 vs. placebo | 29 Participants; >6 years old; <3 months duration of T1D | Increase in suppressive capacity of T-regs |
Studies of prevention of islet autoimmunity or T1D | ||||
[27] | Meta-analysis of four case-control and one cohort study | Vitamin D supplementation (variable doses) | Infants | Four case control studies: risk of T1D decreased; similar findings in cohort study; some evidence of a dose-response effect |
[28] | Population impact number of eliminating a risk factor (PIN-ER-t) Statistical method | Vitamin D supplementation (variable doses) | Babies born in 2012 | For a population of 729,674 babies born in England and Wales in 2012, 374 cases of T1D (out of 1357 total predicted cases) could be prevented over 18 years if all were supplemented with vitamin D |
[31] | Cohort study; assessment every 3 months between 3–48 months, and then every 6 months | Maternal vitamin D supplementation during pregnancy (based on recall); cumulative intake of vitamin D supplements and n-3 FAs analyzed | 8676 children with increased genetic risk for T1D in Finland, Germany, Sweden and the US | Vitamin D supplementation during pregnancy was not associated with risk for development of islet autoantibodies (any/none and cumulative intake) |
Studies examining course or complications of T1D | ||||
[29] | 6-month RCT | 0.25 mcg twice daily of alfacalcidol vs. placebo | 61 participants; 54 completers; 8–15 years old; <8 weeks duration of T1D | Higher fasting C-peptide; lower daily insulin dose |
[30] | 12–24 weeks single arm intervention study | 1000–2000 IUs of vitamin D3 daily | 271 adolescents with T1D with 25(OH)D <15 ng/mL | Improved endothelial function; decreased urinary inflammatory cytokines/chemokines; no change in systolic or diastolic blood pressure, lipids, HbA1C and albumin/creatinine ratio |
[32] | 2-year RCT | 0.25 mcg daily of calcitriol or placebo | 34 participants 11–35 years old with recent onset T1D and high basal C-peptide | No effect on beta cell function |
[33] | Single dose single arm intervention study | Vitamin D3: 100,000 IUs for those 2–10 years old; 160,000 IUs for those >10 years | 40 children <19 years with T1D and vitamin D deficiency (<20 ng/mL) included in ITT analysis | No difference in HbA1C levels at 3 months or at 1 year |
[34] | 6-month RCT | Vitamin D3 60,000 IUs once a month for 6 months | 52 children with T1D 1–18 years old | Higher mean C-peptide level; no difference in HbA1C or insulin requirement |
Obesity, Prediabetes or Type 2 Diabetes | ||||
Adults | ||||
[35] | Single arm intervention study | Vitamin D3 two doses of 100,000 IUs at 2-week intervals | 33 adults with vitamin D deficiency (25(OH)D < 20 ng/mL) and without T2D | No change in mean blood glucose or insulin, or insulin sensitivity (assessed using an OGTT) |
[36] | 6-month RCT | Vitamin D3 4000 IUs daily or placebo | 82 insulin resistant, vitamin D deficient (25(OH)D < 20 ng/mL) South Asian women in New Zealand without T2D | HOMA-IR improved when 25(OH)D level rose to >32 ng/mL; no differences in insulin secretion, CRP, BMI or lipid levels |
[37] | 6-month intervention study | Vitamin D3 20,000 IUs or placebo given twice weekly over 6 months | 104 adults with vitamin D deficiency; 94 completers | No difference in insulin secretion, insulin sensitivity (using a hyperglycemic clamp) or lipids |
[38] | 4-month RCT | Vitamin D3 2500 IUs or placebo daily | 114 post-menopausal women with 25(OH)D between 10–60 ng/mL | No improvement in blood pressure, endothelial function, arterial stiffness, inflammation and CRP |
[39] | 16-week RCT | Vitamin D3 supplementation 200 IUs or placebo daily | 165 healthy women 18–35 years | No change in lipids; modest change in systolic and diastolic blood pressure |
[40] | 5-year RCT | Vitamin D3 20,000 IUs/week or placebo; followed every 6 months | 556 adults 25–80 years old with prediabetes; 503 completers | 25(OH)D increased from ~24 ng/mL to 48 ng/mL with supplementation; no effect on progression to T2D, measures of glucose metabolism, serum lipids or blood pressure in the group as a whole, or in those with vitamin D deficiency |
[41] | Pooled meta-analysis of 28 RCTs | Vitamin D3 supplementation, variable doses | Adults at risk for T2D (no T2D) | No effect on controlling fasting plasma glucose levels, improving insulin resistance, or preventing T2D; stratified analysis suggested a possible beneficial effect in those without obesity, those with prediabetes, when 25(OH)D levels were ≥20 ng/mL, and when the supplemental dose was >2000 IUs per day and given without calcium supplementation |
[42] | RCT | Vitamin D3 4000 IUs or placebo regardless of vitamin D status | 2423 adult participants meeting criteria for prediabetes (2382 randomized) | No differences in baseline 25(OH)D; supplemented group had 25(OH)D levels about twice that in the placebo group; no difference in progression to T2D (9.4 vs. 10.7 events per 100 person-years respectively at a median follow-up of 2.5 years) |
Children | ||||
[43] | 6-month RCT | Vitamin D3 4000 IUs daily or placebo | 35 adolescents with obesity 9–19 years old | Improved HOMA-IR and QUICKI (but not fasting glucose, HbA1C, CRP, IL-6 or TNF-alpha) in those who received vitamin D |
[44] | 1-year open label parallel arm prospective study | Vitamin D3 5000 IUs weekly for 8 weeks vs. no intervention | 70 indigenous Argentinean children vs. 20 non-supplemented children | Improved HDL |
[45] | 12-week RCT | Vitamin D3 300,000 IUs weekly or placebo | 50 children with obesity 10–16 years old | Improved serum insulin and HOMA-IR with no effect on lipids, fasting blood sugar or blood pressure |
[46] | Retrospective study | Vitamin D supplementation | 43 children 3–18 years old with T2D for >12 months and a diagnosis of vitamin D deficiency (25(OH)D < 20 ng/mL) | Decrease in BMI-SDS, HbA1C and ALT in supplemented group |
[47] | 12-week RCT | Vitamin D3 2000 IUs daily or placebo | 58 adolescents with obesity 12–18 years old | No change in fasting glucose, insulin, HOMA-IR, lipids or CRP |
[48] | 12-week RCT | Vitamin D3 two doses (400 IU/day and 2000 IU/day) for 12 weeks | 51 Caucasian adolescents with obesity 12–18 years old; 46 completers | No change in 25(OH)D levels in the in 400 IU/day group and a modest increase in the 2000 IU/day group. No change in fasting HOMA-IR, insulin, glucose or lipid levels post-supplementation |
[49] | 2-year prospective study | Vitamin D3 100,00 IUs/year to both groups | 104 children in Group A (treated in 2014) and 86 in Group B (treated in 2013) | Changes in 25(OH)D levels were significantly associated with lower LDL-C and Apo-B levels. |
[50] | 3-month open label, prospective study | Vitamin D3 100,000 IUs monthly for 3 months | 19 children with obesity and vitamin D deficiency 13–18 years old | No change in endothelial function, fasting lipids, glucose, insulin and CRP values |
[51] | 12-week RCT | Vitamin D3 at either 0, 400, 1000, 2000 or 4000 IU/day for 12 weeks | 323 early pubertal children At baseline, 15% had 25(OH)D levels that were insufficient <25 ng/mL, 6% had levels <16 ng/mL and 1% had levels lower than 12 ng/mL | At baseline, 25(OH)D levels were inversely associated with insulin and HOMA-IR. However, glucose, insulin and insulin resistance increased over 12 weeks in all dosage groups |
[52] | 12-week RCT | Vitamin D3 50,000 IUs per week vs. placebo | 29 African American children with obesity 13–17 years old | No impact on insulin secretion or sensitivity |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Marino, R.; Misra, M. Extra-Skeletal Effects of Vitamin D. Nutrients 2019, 11, 1460. https://doi.org/10.3390/nu11071460
Marino R, Misra M. Extra-Skeletal Effects of Vitamin D. Nutrients. 2019; 11(7):1460. https://doi.org/10.3390/nu11071460
Chicago/Turabian StyleMarino, Rose, and Madhusmita Misra. 2019. "Extra-Skeletal Effects of Vitamin D" Nutrients 11, no. 7: 1460. https://doi.org/10.3390/nu11071460
APA StyleMarino, R., & Misra, M. (2019). Extra-Skeletal Effects of Vitamin D. Nutrients, 11(7), 1460. https://doi.org/10.3390/nu11071460